Неблагоприятные эффекты иммуносупрессивной терапии после пересадки почки

В работе приведен результат изучения источников и обобщение информации о неблагоприятных эффектах иммуносупрессивной терапии, которые играют важную роль в полноценном функционировании трансплантата. В статье показана важность динамического влияния иммуносупрессивной терапии на функционирование трансплантата, необходимость разумного подбора режима и дозировки конкретного лекарственного средства или их комбинации для минимизации неблагоприятных эффектов.

1. Management of Chronic Kidney Disease. A Clinician’s Guide. Second Edition / Editor Mustafa Arıcı. Switzerland: Springer Nature, 2023. 603 p.

2. Cockwell P, Fisher L-A. The global burden of chronic kidney disease. Lancet. 2020; 395 (10225): 662–664.

3. Aiyegbusi O, McGregor E, McManus SK, Stevens KI. Immunosuppression Therapy in Kidney Transplantation. Urol Clin North Am. 2022 May; 49 (2): 345–360. doi: 10.1016/j.ucl.2021.12.010. PMID: 35428439.

4. Johnson RJ, Floege J, Tonelli M. Comprehensive Clinical Nephrology. Seventh Edition. Elsevier, 2024. 1309 p.

5. Alegre ML, Lakkis FG, Morelli AE. Antigen presentation in transplantation. Trends Immunol. 2016; 37 (12): 831– 843.

6. Sypek M, Kausman J, Holt S, Hughes P. HLA epitope matching in kidney transplantation: an overview for the general nephrologist. Am J Kidney Dis. 2018; 71 (5): 720–731.

7. Damage-Associated Molecular Patterns in Human Diseases. Volume 3: Antigen-Related Disorders / Walter Gottlieb Land. Springer Nature Switzerland AG, 2023. 667 p.

8. Granata S, Votrico V, Spadaccino F, Catalano V, Netti GS, Ranieri E et al. Oxidative stress and ischemia/reperfusion injury in kidney transplantation: focus on ferroptosis, mitophagy and new antioxidants. Antioxidants (Basel). 2022; 11 (4): 769. https://www.mdpi.com/2076-3921/11/4/769.

9. Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C et al. 2018 reference guide to the Banff classification of renal allograft Pathology. Transplantation. 2018; 102 (11): 1795–1814.

10. Nakagawa K, Tsuchimoto A, Ueki K, Matsukuma Y, Okabe Y, Masutani K et al. Japan Academic Consortium of Kidney Transplantation Investigators. Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation. Am J Transplant. 2021; 21 (1): 174–185. https://doi.org/10.1111/ajt.16093.

11. Tong A, Gill J, Budde K, Marson L, Reese PP, Rosenbloom D et al. Toward establishing core outcome domains for trials in kidney transplantation: report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops. Transplantation. 2017; 101 (8): 1887–1896.

12. Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after kidney transplantation: an analysis by era and time post-transplant. J Am Soc Nephrol. 2020; 31 (12): 2887–2899.

13. Au EH, Chapman JR, Craig JC, Lim WH, Teixeira-Pinto A, Ullah S et al. Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant. J Am Soc Nephrol. 2019; 30 (3): 471–480.

14. Nambiar P, Silibovsky R, Belden KA. Infection in kidney transplantation. Contemporary Kidney Transplantation. 2018: 307–327.

15. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: Where are we now and where are we going? Transplant Rev (Orlando). 2017 Jan; 31 (1): 10–17. doi: 10.1016/j.trre.2016.10.006. Epub 2016 Oct 11. PMID: 28340885.

16. Bauer AC, Franco RF, Manfro RC. Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols. Curr Pharm Des. 2020; 26 (28): 3440–3450. doi: 10.2174/1381612826666200521142448. PMID: 32436821.

17. Chandra A, Midtvedt K, Åsberg A, Eide IA. Immunosuppression and Reproductive. Health After Kidney Transplantation. Transplantation. 2019 Nov; 103 (11): e325– e333. doi: 10.1097/TP.0000000000002903. PMID: 31397802.

18. Clayton PA, Lim WH, Wong G, Chadban SJ. Relationship between eGFR decline and hard outcomes after kidney transplants. J Am Soc Nephrol. 2016; 27 (11): 3440–3446.

19. Ortiz F, Salonsalmi A, Helanterä I. Associations between dialysis modality and adherence to immunosuppression after kidney transplantation-A single-center study. PLoS One. 2025 Jan 24; 20 (1): e0317435.

20. Kamal J, Doyle A. Immunosuppression and Kidney Transplantation. Handb Exp Pharmacol. 2022; 272: 165– 179. doi: 10.1007/164_2021_546. PMID: 34697664.

21. Суслов ДН. Основные принципы иммуносупрессивной терапии после трансплантации почки. Трансплантология. 2018; 10 (1): 42–49. https://doi.org/10.23873/2074-0506-2018-10-1-42-49.

22. Ватазин АВ, Кильдюшевский АВ, Федулкина ВА, Фаенко АП. Механизмы отторжения почечного аллотрансплантата и иммунологическая толерантность. Нефрология. 2016; 20 (6): 33–41.

23. Cheung CY, Tang SCW. Personalized immunosuppression after kidney transplantation. Nephrology (Carlton). 2022; 27 (6): 475–483. doi: 10.1111/nep.14035.

24. Kuppe C, van Roeyen C, Leuchtle K, Kabgani N, Vogt M, Van Zandvoort M et al. Investigations of glucocorticoid action in GN. J Am Soc Nephrol. 2017; 28 (5): 1408– 1420.

25. Bae S, Garonzik Wang JM, Massie AB, Jackson KR, McAdams-DeMarco MA, Brennan DC et al. Early steroid withdrawal in deceased-donor kidney transplant recipients with delayed graft function. J Am Soc Nephrol. 2020; 31 (1): 175–185.

26. Wojciechowski D, Wiseman A. Long-Term Immunosuppression Management: Opportunities and Uncertainties. Clin J Am Soc Nephrol. 2021 Aug; 16 (8): 1264–1271. doi: 10.2215/CJN.15040920. Epub 2021 Apr.

27. Oxford Handbook of Clinical Immunology and Allergy. Fourth edition / Editor Gavin Spickett. Oxford University Press, 2020. 677 p.

28. El Hennawy HM, Faifi ASA, El Nazer W, Mahedy A, Kamal A, Al Faifi IS et al. Calcineurin Inhibitors Nephrotoxicity Prevention Strategies With Stress on Belatacept-Based Rescue Immunotherapy: A Review of the Current Evidence. Transplant Proc. 2021 Jun; 53 (5): 1532–1540. doi: 10.1016/j.transproceed.2021.03.028. Epub 2021 May 18.

29. Chapel and Haeney’s Essentials of Clinical Immunology. Seventh Edition / Siraj A. Misbah, Gavin P. Spickett, Virgil A.S.H. Dalm. Wiley-Blackwell, John Wiley & Sons Ltd, 2022. 374 p. (P. 158). LCCN 2021061617 (ebook).

30. Mengel M, Mihatsch M, Halloran PF. Histological characteristics of calcineurin inhibitor toxicity – there is no such thing as specicity. Am J Transplant. 2011; 11 (12): 2549–2550.

31. Gardiner KM, Tett SE, Staatz CE. Is conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium justifiable for gastrointestinal quality of life? Drugs R D. 2018; 18 (4): 271–282.

32. Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019; 96 (1): 231–244.

33. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U et al. Everolimus-based, calcineurininhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011; 377 (9768): 837–847.

34. De Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ et al. Early Conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE Trial. Am J Transplant. 2017; 17 (7): 1853–1867.

35. 3C Study Collaborative Group. Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial. Am J Transplant. 2018; 18 (6): 1424–1434.

36. Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA et al. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplant Rev (Orlando). 2019 Oct; 33 (4): 191–199. doi: 10.1016/j.trre.2019.07.001. Epub 2019 Jul 23. PMID: 31377099.

37. Yanik EL, Siddiqui K, Engels EA. Sirolimus effects on cancer incidence after kidney transplantation: a metaanalysis. Cancer Med. 2015; 4 (9): 1448–1459.

38. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012; 12 (5): 1146–1156.

39. Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N et al. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 antiCD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant. 2019; 19 (11): 3035–3045.

40. Pérez-Sáez MJ, Yu B, Uffing A, Murakami N, Borges TJ, Azzi J et al. Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy. Clin Kidney J. 2018; 12 (4): 586–591.

41. Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A et al. Conversion from Calcineurin Inhibitorto Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. J Am Soc Nephrol. 2021 Dec 1; 32 (12): 3252– 3264. doi: 10.1681/ASN.2021050628. Epub 2021 Dec 1.

42. El Hennawy H, Safar O, Al Faifi AS, El Nazer W, Kamal A, Mahedy A et al. Belatacept rescue therapy of CNI-induced nephrotoxicity, meta-analysis. Transplant Rev (Orlando). 2021 Dec; 35 (4): 100653. doi: 10.1016/j.trre.2021.100653. Epub 2021 Sep 21.

43. Choi M, Bachmann F, Wu K, Lachmann N, Schmidt D, Brakemeier S et al. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept. BMC Nephrol. 2020 Aug 20; 21 (1): 354. doi: 10.1186/s12882-020-01992-6. PMID: 32819287; PMCID: PMC7439694.

44. Ulloa CE, Anglicheau D, Snanoudj R, Scemla A, Martinez F, Timsit MO et al. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. Transplantation. 2019 Oct; 103 (10): 2150– 2156. doi: 10.1097/TP.0000000000002592. PMID: 30720681.

45. Zhang H, Wang Z, Zhang J, Gui Z, Han Z, Tao J et al. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation. Front Immunol. 2021 Feb 24; 12: 618737. doi: 10.3389/fimmu.2021.618737.

46. Tawhari I, Hallak P, Bin S, Yamani F, Safar-Boueri M, Irshad A et al. Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients. Front Immunol. 2022 Dec 19; 13: 1096881. doi: 10.3389/fimmu.2022.1096881.

47. Kervella D, Blancho G. New immunosuppressive agents in transplantation. Presse Med. 2022 Dec; 51 (4): 104142. doi: 10.1016/j.lpm.2022.104142. Epub 2022 Oct 15. PMID: 36252821.

48. Uro-Coste C, Atenza A, Heng AE, Rouzaire PO, Garrouste C. Abatacept Rescue Therapy in Kidney Transplant Recipients: A Case Series of Five Patients. Transpl Int. 2022 Aug 12; 35: 10681. doi: 10.3389/ti.2022.10681.

49. Badell IR, Karadkhele GM, Vasanth P, Farris AB 3rd, Robertson JM, Larsen CP. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation. Am J Transplant. 2019 Aug; 19 (8): 2342–2349. doi: 10.1111/ajt.15319. Epub 2019 Mar 12. PMID: 30768841.

50. Bertrand D, Brunel M, Lebourg L, Scemla A, Lemoine M, Amrouche L et al. Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France. Transpl Int. 2023 Jul 24; 36: 11328. doi: 10.3389/ti.2023.11328.

51. Kazory A, Ducloux D. Renal transplantation and polyomavirus infection: recent clinical facts and controversies. Transpl Infect Dis. 2003; 5 (2): 65–71.

52. Cohen-Bucay A, Ramirez-Andrade SE, Gordon CE, Francis JM, Chitalia VC. Advances in BK virus complications in organ transplantation and beyond. Kidney Med. 2020; 2 (6): 771–786.

53. Hirsch HH, Randhawa PS; AST Infectious diseases Community of Practice. BK polyomavirus in solid organ transplantation-guidelinesfrom the American Society of Transplantation infectious diseasesCommunity of Practice. Clin Transpl. 2019; 33 (9): e13528.

54. Spasovski G, Trajceska L, Rambabova-Bushljetik I. Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date. Expert Opin Pharmacother. 2022 Aug; 23 (12): 1397–1412. doi: 10.1080/14656566.2022.2102418. Epub 2022 Jul 19. PMID: 35835450.

55. Lehner LJ, Staeck O, Halleck F, Liefeldt L, Bamoulid J, Budde K. Need for optimized immunosuppression in elderly kidney transplant recipients. Transplant Rev (Orlando). 2015 Oct; 29 (4): 237–239. doi: 10.1016/j.trre.2015.08.001. Epub 2015 Aug 15. PMID: 26411381.

56. Федулкина ВА, Ватазин АВ, Кильдюшевский АВ, Зулькарнаев АБ, Губина ДВ. Рациональная поддерживающая иммуносупрессивная терапия для реципиентов почечного трансплантата пожилого возраста. Обзор литературы. Нефрология. 2022; 26 (2): 25–33. https://doi.org/10.36485/1561-6274-2022-26-2-25-33.

57. He L, Wang B, Wang X, Liu Y, Song X, Zhang Y et al. Uncover diagnostic immunity/hypoxia/ferroptosis/epithelial mesenchymal transformation-related CCR5, CD86, CD8A, ITGAM, and PTPRC in kidney transplantation patients with allograft rejection. Ren Fail. 2022 Dec; 44 (1): 1850–1865. doi: 10.1080/0886022X.2022.2141648. PMID: 36330810; PMCID: PMC9639483.